Recently, Evonik, a company that specializes in implantable medical devices, and BellaSeno GmbH, which is a global provider for 3D printed absorbable scaffolds, made an announcement of a partnership for the development of RESOMER® bioresorbable polymer for a new technology used for breast implants.
Previously, BenoSeno has provided the most premium quality breast scaffold products for breast implants and similar purposes. In the newly designed technology, the company aims to add a RESOMER® in its Senella® alongside a proprietary procedure for manufacturing.
These breast implants, which will soon be available in the market in a variety of shapes and sizes, can be used per need. Hence, a person who has just had reconstruction surgery, revision surgery, or is getting an augmentation can opt for using RESOMER® polymer in the process.
Not only is the new technology and the used polymer improved and better than before but also comes with a better degradation profile. Such changes allow the scaffold to be safer as it absorbs at a rate similar to the tissues surrounding it in a person.
Secondly, there is no use of silicone in the design of the new breast implant. This is because evidence from clinical trials and research have shown that silicone implants have an association with health issues such as capsular contracture. In addition, there are also higher chances of injury, rupture, and deflation with silicone breast implants.
The clinical trials for Senella® scaffolds with RESOMER® in humans are set to begin soon. These trials will take place in Germany and the RESOMER® polymer will be provided by Evonik.
Dr. Jean-Luc Herbeaux, SVP and General Manager of the Health Care business line, says that collaboration between Evonik and BellaSeno is fundamental due to the rising demands for breast augmentation, reconstruction, and other procedures. He further adds how the partnership can greatly improve the whole procedure and ensure better safety.
Consequently, the satisfaction rates among people undergoing procedures using breast implants will be higher and the quality of life following the surgery will be much better in comparison with the life quality after having silicone breast implants.
The Chief Executive Officer and Co-founder of BellaSeno, Dr. Simon Champ, on the other hand, also comments how the company is proud to be working with Evonik in the joint venture as it develops technology as well as paves the way for better health and safer surgeries for the general public.
In recent years, the number of people going for breast implants has greatly increased. According to the statistics by the American Society of Plastic Surgeries, it is the most common cosmetic surgery performed in the country. Therefore, there are also various campaigns for awareness regarding safety in breast-related procedures.
Clinicians and health professionals advise on using the safest type of implants and visiting certified and experienced surgeons in order to avoid any post-surgery complications that can cause serious damage to the body and may even require the implants to be removed.
The collaboration between BellaSeno and Evonik will further add to ensuring safety in breast surgeries and improving lifestyles in people.